This Article Free Full Text (Free OnlineFirst PDF) All Versions of this Article: 0192623307311412v1 36/2/345    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Westwood, F. R. Articles by Randall, K. Search for Related Content PubMed PubMed Citation Articles by Westwood, F. R., PhD, FRCPa Articles by Randall, K. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Muscle Disorders Statins Social Bookmarking                         What's this?

Rosuvastatin: Characterization of Induced Myopathy in the Rat

^* To whom correspondence should be addressed. E-mail: russell.westwood{at}astrazeneca.com.

	Abstract

Rosuvastatin is a relatively new member of the statin family (HMG-CoA reductase inhibitors), with superior lipid-lowering effects and a pattern of clinical side effects, including a low incidence of myopathy, similar to other widely prescribed statins. This article describes investigations of myopathy in the rat following administration of very high doses of rosuvastatin. The nature of the changes were found to be entirely consistent with those seen with other statins, including a differential sensitivity of muscle fibers (with glycolytic fibers [type IIB] the most sensitive and oxidative fibers [type I] the least), a delay of approximately 10 days after the start of oral dosing before necrosis was apparent, and ultrastructural alterations appearing first in mitochondria. In addition, the development of myopathy was prevented by coadministration of mevalonate, the product of HMG-CoA reductase. The findings illustrate a pattern of induced myopathy in the rat directly attributable to inhibition of HMG-CoA reductase that is entirely consistent between the various statins, with the oral dose required to produce the changes being a differentiating feature (based on these new data and a previously reported study from the same laboratory): cerivastatin dose less than simvastatin, and simvastatin dose less than rosuvastatin.

First published on March 24, 2008, doi:10.1177/0192623307311412

Toxicologic Pathology 2008;36:345.

A more recent version of this article appeared on February 1, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. E. Mallinson, D. Constantin-Teodosiu, J. Sidaway, F. R. Westwood, and P. L. Greenhaff Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy J. Physiol., January 1, 2009; 587(1): 219 - 230. [Abstract] [Full Text] [PDF]